Cullinan Therapeutics, Inc. (CGEM)
Nasdaq · Healthcare · Biotechnology
$16.04+3.42%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $986M
- 52-week range
- $5.71 – $23.19
- 52-week change
- +165.58%
- EPS (trailing)
- −$3.11
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 14, 2026
Fiscal year to Dec 2025
- Net income
- −$220M
- Free cash flow
- −$176M
From the company’s annual report on SEC EDGAR.
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc.
Headquarters: Cambridge, United States · 109 employees · cullinantherapeutics.com